A bispecific antibody is designed to bind both an antigen on a cancer cell and an antigen on a normal T cell so that they are linked to one another. Connecting the two cells activates and enables the T cell to directly kill the cancer cell.
HaemaLogiX is currently advancing the discovery of bispecific antibodies, next-generation immunotherapies. The Kappa bispecific antibody and Lambda bispecific antibody are designed to attach to multiple myeloma plasma cells expressing either KMA or LMA and to simultaneously engage a T cell through its specific cell surface target called CD3. This dual action brings the patient’s own T cells into direct contact with the myeloma cancer cells, enabling targeted T cell mediated cell killing.
The key advantage of bispecific antibodies lies in their dual-targeting mechanism, which enhances immune activation by engaging two critical immune pathways. Additionally, they hold strong potential for combination therapy, offering synergy when used alongside CAR-T cell therapies or monoclonal antibodies to drive deeper and more durable treatment responses.